2/18/2021 |
Takeda Receives Prestigious EURORDIS 2021 Black Pearl Award for Patient Engagement |
gurufocus.com |
... Takeda has been announced the winner of the EURORDIS 2021 Award for Patient Engagement in recognition of the company’s unwavering commitment to rare disease patients and its comprehensive partnerships with the rare disease patient community .The annual EURORDIS Black Pearl awards ceremony is a celebration of achievements and exceptional work in this space and is held every February marking Rare Disease Day. Giles Platford, President Europe and Canada, will ... |
2/18/2021 |
Takeda Receives Prestigious EURORDIS 2021 Black Pearl Award for Patient Engagement |
neuro-central.com |
... Takeda has been announced the winner of the EURORDIS 2021 Award for Patient Engagement in recognition of the company’s unwavering commitment to rare disease patients and its comprehensive partnerships with the rare disease patient community .The annual EURORDIS Black Pearl awards ceremony is a celebration of achievements and exceptional work in this space and is held every February marking Rare Disease Day. Giles Platford, President Europe and Canada, will ... |
2/17/2021 |
Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health |
Yahoo News |
... among women of reproductive age linked to increased risk of miscarriage, problems during pregnancy and fertility issues 1,2,3The companies aim to leverage world-leading microbiome technology expertise to bring new therapeutics to this patient community and help more people build familiesThe agreement builds on the existing collaboration between MyBiotics and Ferring in developing live microbiota-based therapeutics for women’s healthFerring Pharmaceuticals, Rebiotix Inc., a Ferring Company ... |
2/17/2021 |
Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health |
stateofaffairs.news |
... among women of reproductive age linked to increased risk of miscarriage, problems during pregnancy and fertility issues 1,2,3 The companies aim to leverage world-leading microbiome technology expertise to bring new therapeutics to this patient community and help more people build families The agreement builds on the existing collaboration between MyBiotics and Ferring in developing live microbiota-based therapeutics for women’s healthFerring Pharmaceuticals, Rebiotix Inc., a Ferring Company ... |
2/17/2021 |
Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health |
itbusinessnet.com |
... among women of reproductive age linked to increased risk of miscarriage, problems during pregnancy and fertility issues 1,2,3 The companies aim to leverage world-leading microbiome technology expertise to bring new therapeutics to this patient community and help more people build families The agreement builds on the existing collaboration between MyBiotics and Ferring in developing live microbiota-based therapeutics for women’s healthST PREX, Switzerland & ROSEVILLE, Minn. & ROHOVOT, Israel ... |
2/17/2021 |
Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health |
firstwordpharma.com |
... among women of reproductive age linked to increased risk of miscarriage, problems during pregnancy and fertility issues 1,2,3 The companies aim to leverage world-leading microbiome technology expertise to bring new therapeutics to this patient community and help more people build families The agreement builds on the existing collaboration between MyBiotics and Ferring in developing live microbiota-based therapeutics for women's healthST PREX, Switzerland & ROSEVILLE, Minn. & ROHOVOT, Israel--( BUSINESS ... |
2/16/2021 |
Lymphangiomatosis & Gorham's Disease Alliance |
forumfornonprofits.org |
... hope to and improve the quality of life of patients with generalized lymphatic anomaly (GLA), also known as lymphangiomatosis, Kaposiform lymphangiomatosis (KLA), and Gorham-Stout disease (GSD) by providing support to members of the patient community and their families; education for the community, professionals, and the general public; and supporting research that will improve understanding of these diseases and establish best practices for their diagnosis and management. Disease Information What ... |
2/11/2021 |
ORYZON Announces FDA Orphan Drug Designation Granted to iadademstat for Treatment of Acute Myeloid Leukemia |
Business Insider |
... factors involved in leukemia and other cancers.“Receiving Orphan Drug Designation for iadademstat in AML is an important recognition of the role that new drugs with new mechanisms of action may bring to this patient community , where we do not yet have any potentially curative medicines besides stem cell transplant. Iadademstat is showing a high overall response rate of 85% in our ongoing clinical Phase II study ALICE, with a ... |
2/11/2021 |
The compound is currently in Phase II Now has orp |
wapakdailynews.com |
... factors involved in leukemia and other cancers.“Receiving Orphan Drug Designation for iadademstat in AML is an important recognition of the role that new drugs with new mechanisms of action may bring to this patient community , where we do not yet have any potentially curative medicines besides stem cell transplant. Iadademstat is showing a high overall response rate of 85% in our ongoing clinical Phase II study ALICE, with a ... |
2/11/2021 |
The Ridgway Record |
ridgwayrecord.com |
... factors involved in leukemia and other cancers.“Receiving Orphan Drug Designation for iadademstat in AML is an important recognition of the role that new drugs with new mechanisms of action may bring to this patient community , where we do not yet have any potentially curative medicines besides stem cell transplant. Iadademstat is showing a high overall response rate of 85% in our ongoing clinical Phase II study ALICE, with a ... |
2/4/2021 |
COVID vaccine: Those with underlying health conditions are left behind |
USA Today |
... of death for individuals with CF in the United States was 32.4 years old . And that's under the best of circumstances, not during a pandemic. When cases of COVID-19 started mounting nationwide, our patient community was quickly urged to stock up on supplies and stay home. Like the millions of Americans with underlying conditions, our goal was to prevent exposure to COVID-19. More than 30,000 people in the ... |